Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

In the phase III RESTORE‐IMI 2 study (ClinicalTrials.gov: NCT02493764), the combination antibacterial agent imipenem/cilastatin/relebactam (IMI/REL) demonstrated noninferiority to piperacillin/tazobactam for the end points of all‐cause mortality at day 28 and favorable clinical response at the early...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Munjal, Bellanti, Francesco, Daryani, Naveen M., Noormohamed, Nadia, Hilbert, David W., Young, Katherine, Kulkarni, Pooja, Copalu, William, Gheyas, Ferdous, Rizk, Matthew L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841461/
https://www.ncbi.nlm.nih.gov/pubmed/34704389
http://dx.doi.org/10.1111/cts.13158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841461/
https://www.ncbi.nlm.nih.gov/pubmed/34704389
http://dx.doi.org/10.1111/cts.13158

Ejemplares similares